Summary of article from Foley & Lardner LLP, by Antoinette F. Konski:
Key findings include a reversal of the 2023 decline in Healthtech investments, stable Med Device investments driven by first-financing deals, and a notable 35% increase in Biopharma investments with significant private deals. The Dx/Tools sector saw a decline in first-financing deals but benefited from growth investors for companies nearing commercialization. Overall, the report highlights increased investment activity across all sectors, with heightened IPO interest and significant private M&A deals in Biopharma.